China Nuokang Bio-Pharmaceutical Inc. (NKBP) Provides Update on Kaitong  
12/2/2010 11:30:30 AM

BEIJING, Dec. 1, 2010 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the manufacturing license for Kaitong has been issued by the State Food and Drug Administration ("SFDA"). Kaitong is one of the Company's key pipeline candidate products that was in-licensed from the Company's development partner, Jilin Yuhua. The Company continues to expect revenue contribution from the product in early 2011.